Cerenome (PSTV) Net Margin (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Net Margin of 675.68% for Q1 2026, down 29013.0% year-over-year from N/an in Q1 2025, and down 76.67% quarter-over-quarter from 382.44% in Q4 2025.
Cerenome (PSTV) Net Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Net Margin for 14 consecutive years, with 675.68% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 29013.0% year-over-year to 675.68%; the TTM figure through Mar 2026 stood at 349.46% (down 5142.0% YoY), while the FY2025 annual figure was 788.26%, down 15301.0% from the prior year.
- Net Margin declined to 675.68% in Q1 2026 per PSTV's latest filing, from 382.44% in the prior quarter.
- Across five years, Net Margin topped out at 108.71% in Q2 2025 and bottomed at 7149.32% in Q3 2022.
- Historically, Net Margin has averaged 1077.03% across 5 years, with a median of 301.37% in 2023.
- Annual changes were most pronounced in 2023 — Net Margin surged 688972 bps — and 2026, when it slumped 29013 bps.
- Plus Therapeutics' Net Margin stood at 4455.12% in 2022, then surged by 93 bps to 301.37% in 2023, then climbed by 6 bps to 282.79% in 2024, then plunged by 35 bps to 382.44% in 2025, then sank by 77 bps to 675.68% in 2026.
- Business Quant data shows PSTV's Net Margin at 675.68% in Q1 2026, 382.44% in Q4 2025, and 316.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -2,191.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -675.68% |
| Dec 31, 2025 | -382.44% |
| Sep 30, 2025 | -316.69% |
| Jun 30, 2025 | -108.71% |
| Mar 31, 2025 | -385.55% |
| Dec 31, 2024 | -282.79% |
| Sep 30, 2024 | -259.82% |
| Jun 30, 2024 | -285.93% |
| Mar 31, 2024 | -194.45% |
| Dec 31, 2023 | -301.37% |
| Sep 30, 2023 | -259.60% |
| Jun 30, 2023 | -143.84% |
| Mar 31, 2023 | -954.20% |
| Dec 31, 2022 | -4,455.12% |
| Sep 30, 2022 | -7,149.32% |
| Mar 31, 2019 | -97.58% |
| Dec 31, 2018 | -141.35% |
| Sep 30, 2018 | -452.56% |
| Jun 30, 2018 | -208.18% |
| Mar 31, 2018 | -651.30% |